ID | 1126 |
Name of the vaccine | Bexsero (In UK) |
Microbe | Bacteria |
Disease name | Meningococcal disease |
Name of bacteria | Neisseria meningitidis |
Type of vaccine | Recombinant |
Nucleic acid content | DNA |
Age | 2 months and older |
Description of the vaccine | Meningococcal group B vaccine (rDNA, component, adsorbed). |
Name of the manufacturer | GSK Vaccines |
Name of the manufacturing country | Sovicille (SI), Italy |
Year of manufacture | 2015 |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative diplococcus. |
Efficacy | 72% reduction in invasive MenB disease in infants in 2nd programme and 60% reduction in the 3rd programme. |
Vaccine formulation | Suspension for injection |
Dosage | Dose - 0.5 ml. Infants 2-5 months: two or three injections followed by booster.
Infants 6 to 11 months at time of first dose: two injections with gap of at least 2 months and a booster.
Children 12 to 23 months : two injections and a booster after an interval of 12 to 23 months.
After 2 years of age: two injections with interval of at least 1 month. |
Mechanism of action | Specifically stimulating the body’s natural defence system. |
Route of administration | Intramuscular |
Indications | To help protect against disease caused by the Neisseria meningitidis group B bacteria. Also recommended for people with some long-term health conditions who are at greater risk of complications from this disease. |
Export | Distributed by - GlaxoSmithKline UK Limited, United Kingdom |
Approval | NA |
Adjuvant | NA |
Repurposing | For MenW strain also. |
Side effects of vaccine | Very common (in children): pain, swelling, redness and hardness of the skin at the injection site, fever, loss of appetite, sleepiness, feeling irritable, unusual crying, vomiting, headache, diarrhoea, skin rash, painful joints.
Very common (in adults) : pain at the injection site, painful muscles and joints, nausea, headache and feeling unwell.
|
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://vk.ovg.ox.ac.uk/vk/menb-vaccine |
Other name | NA |
Additional Links | NA
|